Nationwide Trends in Incidence, Healthcare Utilization, and Mortality in Hospitalized Acute Myocardial Infarction Patients in Taiwan

Acute Myocardial Infarction Clinical Trial

Official title:

Nationwide Trends in Incidence, Healthcare Utilization, and Mortality in Hospitalized Acute Myocardial Infarction Patients in Taiwan

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05974397
• Other study ID #: CLCZ696BTW05
• Status: Completed
• Start date: September 30, 2021
• Est. completion date: July 22, 2022

Study information

• Verified date: July 2023
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This was a retrospective study using the Taiwan's National Health Insurance Research Database (NHIRD). The study employed two study designs for different purposes as follows:

• A cross-sectional analysis was conducted to explore the annual incidence trends.

• A longitudinal cohort study was conducted to assess baseline characteristics, treatment patterns, long-term healthcare utilization, and cause-specific mortality among incident AMI patients.

In each part, the study was conducted for AMI, and separately for ST-segment elevation and non-ST- segment elevation myocardial infarction (STEMI and NSTEMI)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 124018
• Est. completion date: July 22, 2022
• Est. primary completion date: July 22, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

Cross-sectional analysis:

• Patients aged 20 years and older.

• Patients who had been admitted for AMI, defined as primary or first secondary diagnosis of AMI between 2014 and 2020.

• The diagnosis of AMI/ STEMI/ NSTEMI was identified by the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes and 10th revision (ICD-10-CM) codes.

• Incident cases of AMI hospitalization were defined as no history of AMI-related hospitalization or outpatient visit within 1 year before admission.

Longitudinal analysis:

Patients aged 20 years and older.

• Patients who had been admitted for AMI, defined as primary or first secondary diagnosis of AMI between 2014 and 2017.

• The diagnosis of AMI/ STEMI/ NSTEMI was identified by ICD-9-CM codes and ICD-10-CM codes. (The ICD-9-CM code and ICD-10-CM codes were the same as above)

• Incident cases of AMI hospitalization were defined as no history of AMI-related hospitalization or outpatient visit within 1 year before admission.

• The cohort entry date was defined as the admission date of incident AMI hospitalization, and the index date was defined as the discharge date of incident hospitalization.

Exclusion Criteria:

None specified

Related Conditions & MeSH terms

• Acute Myocardial Infarction
• Infarction
• Myocardial Infarction

Locations

Country	Name	City	State
Taiwan	Novartis	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean age of patients		12 months
Primary	Number of male patients		12 months
Primary	Year of patient entry into cohort		12 months
Primary	Number of patients with AMI in Taiwan		12 months
Primary	Number of patients with STEMI in Taiwan		12 months
Primary	Number of patients with NSTEMI in Taiwan		12 months
Primary	Number of AMI patients with comorbidities		Up to 3 years
Primary	Number of patients with treatment for AMI		Up to 3 years
Primary	Number of STEMI patients with comorbidities		Up to 3 years
Primary	Number of patients with treatment for STEMI		Up to 3 years
Primary	Number of NSTEMI patients with comorbidities		Up to 3 years
Primary	Number of patients with treatment for NSTEMI		Up to 3 years
Primary	Number of mortalities among AMI patients		Up to 3 years
Primary	Number of mortalities among STEMI patients		Up to 3 years
Primary	Number of mortalities among NSTEMI patients		Up to 3 years
Primary	Number of AMI patients with outpatient visits		Up to 3 years
Primary	Number of AMI patients with emergency room visits		Up to 3 years
Primary	Number of AMI patients with hospitalizations		Up to 3 years
Primary	Length of hospital stay for AMI patients		Up to 3 years
Primary	Direct medical costs for AMI patients		Up to 3 years
Primary	Number of STEMI patients with outpatient visits		Up to 3 years
Primary	Number of STEMI patients with emergency room visits		Up to 3 years
Primary	Number of STEMI patients with hospitalizations		Up to 3 years
Primary	Length of hospital stay for STEMI patients		Up to 3 years
Primary	Direct medical costs for STEMI patients		Up to 3 years
Primary	Number of NSTEMI patients with outpatient visits		Up to 3 years
Primary	Number of NSTEMI patients with emergency room visits		Up to 3 years
Primary	Number of NSTEMI patients with hospitalizations		Up to 3 years
Primary	Length of hospital stay for NSTEMI patients		Up to 3 years
Primary	Direct medical costs for NSTEMI patients		Up to 3 years